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ABSTRACT - Purpose: To provide a situation assessment of services for people with epilepsy in the context
of primary health care, as part of the Demonstration Project on Epilepsy in Brazil, part of the WHO/ILAE/IBE
Global Campaign ‘Epilepsy out of the shadows’. Methods: We performed a door-to-door epidemiologi-
cal survey in three areas to assess the prevalence of epilepsy and its treatment gap. We surveyed a sample
of 598 primary health care workers from diff e rent regions of Brazil to assess their perceptions of the man-
agement of people with epilepsy in the primary care setting. Results: The lifetime prevalence of epilep-
sy was 9.2/1,000 people [95% CI 8.4-10.0] and the estimated prevalence of active epilepsy was 5.4/1,000
people. Thirty-eight percent of patients with active epilepsy were on inadequate treatment, including 19%
who were taking no medication. The survey of health workers showed that they estimated that 60% of
patients under their care were seizure - f ree. They estimated that 55% of patients were on monotherapy
and that 59% had been re f e rred to neurologists. The estimated mean percentage of patients who were
working or studying was 56%. Most of the physicians (73%) did not feel confident in managing people
with epilepsy. Discussion: The epidemiological survey in the areas of the Demonstration Project showed
that the prevalence of epilepsy is similar to that in other resource-poor countries, and that the treatment
gap is high. One factor contributing to the treatment gap is inadequacy of health care delivery. The situ-
ation could readily be improved in Brazil, as the primary health care system has the key elements re q u i re d
for epilepsy management. To make this effective and efficient re q u i res: i) an established re f e rral network,
ii) continuous provision of AEDs, iii) close monitoring of epilepsy management via the notification system
(Sistema de Informação da Atenção Básica - SIAB) and iv) continuous education of health pro f e s s i o n a l s .
The educational program should be broad spectrum and include not only medical management, but also
psycho-social aspects of epilepsy.
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Projeto demonstrativo em epilepsia no Brasil: avaliação situacional
RESUMO - Objetivo: Avaliar a situação da assistência à epilepsia no contexto da atenção primária sob o
P rojeto Demonstrativo em epilepsia no Brasil, parte da Campanha Global Epilepsia Fora das Sombras da
W H O / I L A E / I B E . Método: Fizemos um levantamento epidemiológico para definir a prevalência e lacuna
de tratamento em epilepsia. Avaliamos a percepção de 598 profissionais de saúde da atenção básica de
d i f e rentes regiões do Brasil sobre epilepsia e seu manejo na rede básica de saúde. Resultados: A pre v a l ê n-
cia acumulada de epilepsia foi de 9,2/1000 pessoas (95%IC= 8,4-10) e a prevalência estimada de epilepsia
ativa foi de 5,4/1000 pessoas. Trinta e oito porcento dos pacientes com epilepsia ativa estavam sendo trata-
dos inadequadamente, incluindo 19% que estavam sem medicação. A enquete com os profissionais de
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saúde mostrou que a média estimada de pacientes livre de crises sob os cuidados dos mesmos era de 60%.
A média estimada de porcentagem em monoterapia era de 55%. A média estimada de porcentagem de
referência para neurologistas era de 59%. A média estimada de porcentagem de pacientes que estavam
trabalhando ou estudando era de 56%. A maioria dos médicos não se sente confiante em atender uma
pessoa com epilepsia. Discussão: A análise situacional da Fase I - estudo epidemiológico nas áreas de
interesse do PD mostrou que a prevalência da epilepsia é similar a outros países em desenvolvimento e a
lacuna de tratamento é grande. Um dos fatores importantes para a lacuna de tratamento é a falta de ade-
quação à assistência na atenção básica. Essa situação pode ser re v e rtida no Brasil, pois os elementos chaves
existem na rede básica para o manejo de pessoas com epilepsia. Entretanto, para torna efetivo e eficiente
é preciso i) estabelecimento de um sistema de referência e contra-referência, ii) fornecimento contínuo de
medicação anti-epiléptica, iii) monitorização de manejo de pessoas com epilepsia através de sistema de
notificação (SIAB – Sistema de Informação da Atenção Básica), e iv) educação continuada de profissionais
de saúde. O programa educacional deve ser amplo incluindo não somente manejo médico, mas também
aspectos psico-sociais. 
PALAVRAS-CHAVE: epilepsia, droga-antiepiléptica, atenção primária, crise epiléptica.
Brazil is a South American country of continental
dimensions (8,511,965 km2). It is divided into 27 fed-
eral units, and in 2000 had a population of 170 mil-
lion. The gross internal product (GIP) of the country
(2000) averaged 6,560 Brazilian Reais (~ US$ 2,630)
per capita, with striking regional diff e rences. The un-
employment rate was estimated as around 6% in
m e t ropolitan areas in 2000. The illiteracy rate de-
c reased from 25.5% in 1980 to 20% in 1991 and, in
some regions in those less than 24 years old, is four
percent. Thirty years ago, the population growth in
Brazil was three percent per year, but presently is 1.9
p e rcent mainly due to a falling birth rate. Eighty per-
cent of the population has become urbanized in the
last three decades, a fact which may have contributed
to this marked decline in population growth.
Brazil has a well-stru c t u red federal constitution
which states that health is the right of every citizen
and that it is the duty of the State to provide this.
This has been stated in law since 1990 when the Uni-
fied Health System (Sistema Único de Saúde [SUS])
was created. SUS comprises the combined health care
d e l i v e ry of local, state, and federal organisations and
institutions. The same law allows for the coexistence
of private medicine in its various forms. It is estimat-
ed that SUS provides health care coverage to 77% of
the population.
Epilepsy is a common neurological disorder and
a ffects approximately 50 million people worldwide,
of whom five million live in Latin America and the
Caribbean1. Few epidemiological studies have been
c a rried out in Brazil. In 1986 the prevalence of the
epilepsies in Greater São Paulo was 11.9/1,000 (SP)2,
and in 1992 prevalences of 16.5 and 20.3/1,000 were
found for active and inactive epilepsies respectively
in Porto Alegre (RS)3. The prevalence in São José do
Rio Preto was 18.6/1,0004. According to the Ministry
of Health, the epilepsies rank 30t h among causes for
hospitalization. Epilepsy was responsible for over 40
thousand hospital admissions per year in the early
1990s (approximately 0.54/1,000 inhabitants). It is
unclear how many of these admissions are of patients
in status epilepticus or with serial seizures.
Risk factors such as parasitic diseases may explain
the high incidence of epilepsy in developing coun-
tries, including Brazil. Neuro c y s t i c e rcosis is the most
p revalent brain disease caused by parasites, and is
endemic in the southeastern, south, and central-west-
e rn regions of Brazil. It is the most frequently diag-
nosed risk factor associated with epilepsy in adults
in these areas. Perinatal brain damage is also said to
contribute to the high incidence of epilepsy, partic-
ularly in regions with inadequate ante-natal care .
High incidence of road traffic accidents leading to
traumatic brain injury may also be an important risk
factor for epilepsy. Thus the basic strategy for prima-
ry prevention of epilepsy in a country like Brazil
should include improved ante- and peri-natal care ,
c o n t rol of infectious and parasitic diseases, and re d u c-
tion of brain injury due to trauma and stroke.
In addition to the increased risk of morbidity and
m o rtality associated with epilepsy, patients face stig-
ma placed on them by the community. Stigmatization
p revents patients disclosing their condition, and may
stop them seeking treatment. This clearly has an
impact on employment, education, and ultimately
on a patient’s quality of life and societal inclusion.
Knowledge about epilepsy by people in the general
population is generally unsatisfactory and is surro u n d-
ed by misperceptions. The lack of current inform a-
tion about epilepsy helps to perpetuate old pre j u-
dices against epilepsy.
Treatment with first line antiepileptic drugs (AEDs)
medication can render up to 70-80% of patients seizure -
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f re e5. In 1999, the most commonly prescribed AEDs in
Brazil were carbamazepine (29%), clonazepam (22%),
phenobarbital (17%), phenytoin (11%), and valpro a t e
(8%). These prescriptions came mainly from neuro l o-
gists (45%), general practitioners (21%), psychiatrists
(12%), and pediatricians (8%)6. It has been estimated,
h o w e v e r, that 70% of patients in developing countries
do not receive antiepileptic drug tre a t m e n t7. The tre a t-
ment gap has been estimated as being around 40% in
P o rto Alegre in Southern Brazil. A surv e y8 in two cities
(Campinas and São José do Rio Preto) estimated that
the quantity of AEDs provided by the government in
2000 would treat 55% and 60% in each city re s p e c t i v e-
ly of the estimated pool of patients with epilepsy under
SUS care.
Some patients with partial epilepsy re f r a c t o ry to
c u rrent AEDS are potentially candidates for surg i c a l
t reatment, which can be highly effective, achieving
total seizure control in up to two thirds of people.
Candidates for epilepsy surgery are referred mainly
to centres affiliated to the Federal Epilepsy Pro g r a m
S e rvices or to private services. Curre n t l y, despite the
many emerging centres for surgical treatment, only
eight are approved by the Ministry of Health for
epilepsy surg e ry; these are in São Paulo (5); Goiás (1),
Paraná (1) and Rio Grande do Sul (1). 
Since 1997 a global eff o rtto drive epilepsy out of
the shadows has been promoted by the World Health
O rganization (WHO), the International League A-
gainst Epilepsy (ILAE) and the International Bure a u
of Epilepsy (IBE)9. In 2002 the Global Campaign en-
tered the second phase of its activity, setting up de-
monstration projects (DPs)1 0. The main objective of
a DP is to demonstrate that a given set of pro c e d u re s
can provide a cost effective way to treat epilepsy1 1.
The participating countries within the second phase
of the Global Campaign were Brazil, China, Zimba-
bwe and Senegal1 2 - 1 4. ASPE (Assistência à Saúde de
Pacientes com Epilepsia), a non-governmental org a n-
ization, was created to execute the DP in Brazil1 5. The
DP (duration four years) was launched in September
2002, and its framework is described in detail in the
Appendix.
This paper brings the results based on pre v i o u s
p u b l i c a t i o n s1 6 , 1 7 of the phase I of the Demonstration
P roject on Epilepsy part of the WHO/ILAE/IBE Global
Campaign Against Epilepsy, in Brazil1 5. We aim to pro-
vide a concise overview of the situation re g a rd i n g :
i) the pharmacological treatment gap in the study
a rea of the DP1 6 and ii) the perceptions of primary
health care workers on the management of people
with epilepsy in the primary care setting17.
SITUATION ASSESSMENT
In Phase I of the DP, a door-to-door community
s u rvey to assess the prevalence and treatment gap
of epilepsy was conducted in three areas of two mu-
nicipalities (Campinas and São José do Rio Pre t o
[SJRP]) in Southeast Brazil. The total population in
these three areas was 96,300 people. A validated epi-
demiological questionnaire with sensitivity 95.8%
and specificity 97.8% for epilepsy screening was used,
and a neurologist further ascertained the positive
cases. A validated questionnaire based on a house-
hold possessions inventory was used to produce a
socio-economic classification that ranges from Class
Table 1. Treatment of active epilepsy according to social classes in Campinas and São José do Rio Preto16.
Social
classes
Adequate treatment Inadequate treatment
Active
epilepsy
(total number)
Treatment gap
(% [95%CI]) 
Mono-
therapy
Poly-
therapy
Inadequate
dosage
(% [95% CI])
Non treated
(% [CI])
Unknown
(% [95%CI])
A 2 2 1
(14.3 [2.6 to 51.3])
1
(14.3 [2.6 to 51.3])
1
(14.3 [2.6 to 51.3])
7 3
(42.9 [6 to 79])
B 21 9 1
(2.4 [0.4 to 12.6])
5
(12.2 [5.3 to 25.5])
5
(12.2 [5.3 to 25.5])
41 11
(26.8 [13 to 40])
C 50 32 22
(15.4 [10.4 to 22.2])
31
(21.7 [15.7 to 29.1])
8
(5.6 [2.9 to 10.7])
143 61
(42.7 [35 to 51])
D+E 46 17 11
(11.3 [6.5 to 19.2])
18
(18.6 [12.1 to 27.4])
5
(5.2 [2.2 to 11.5])
97 34
(35.1 [26 to 45])
Not
classified
2 – – – 2 –
Total 121 60 35
(12.1 [8.8 to 16.3])
55
(19.0 [14.9 to 23.9])
19
(6.6 [4.2 to 10])
290 109
(37.6 [32.2 to 43.3] )
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A1 (highest) to E (lowest). We defined adequate epi-
lepsy treatment as regular use of antiepileptic dru g s
(AEDs) at standard dosage. The lifetime pre v a l e n c e
of epilepsy was 9.2/1,000 people [95% CI 8.4-10.0]
and the estimated prevalence of active epilepsy was
5.4/1,000 people. The prevalence of active epilepsy
was higher in the more deprived social classes (7.5/
1,000 in Class D+E compared with 1.6/1,000 in Class
A). The prevalence of active epilepsy was also high-
er in elderly people (8.5/1,000 in those aged 60 years
or older). 
Sixty-two percent of people with active epilepsy
w e re on adequate treatment, the remaining 38%
w e re not; this included 19% who were not on any
medication; the figures were similar in diff e rent socio-
economic groups (Table 1). 
The reasons for the treatment gap may be multi-
f a c t o r i a l1 6, ranging from logistic aspects of health
c a redelivery to ignorance of the existence of med-
ical treatment. In our study, the treatment gap was
defined as no or inadequate treatment. The main
reason given by people with active epilepsy who were
not on treatment was that they were not keen on
t reatment (Table 2). It is important to point out that
in this group of patients without medication aro u n d
one quarter either never sought medical treatment
or were not aware of the existence of medical tre a t-
ment for the condition. 
Campinas and São José do Rio Preto are located
in one of the wealthier regions of Brazil, and there
is a good public and private health care system avail-
able. Therefore, our findings are likely to represent
the best scenario in the spectrum of epilepsy man-
agement in Brazil.
To assess the perception of primary health care
workers on the management of people with epilep-
sy in the primary care setting we carried out a sur-
vey of 598 professionals allied to medicine and physi-
cians from the Family Physician Program. The part i c-
ipants of this survey were interviewed using a stru c-
t u red questionnaire during a National Meeting of
Family Physicians. The information collected re f l e c t s
an educated guess rather than “real data” on the
p r i m a ryhealth care system. Nevertheless we believe
that the study is adequate for obtaining an overv i e w
of how primary health care professionals perc e i v e
e p i l e p s y, and the current state of its management in
Brazil. Overall both professionals allied to medicine
and physicians had an appropriate perception of
epilepsy.
The survey of physicians estimated that 0.78%
(n=286, range 0% to 8%, median=0.37%) of the pop-
ulation had consulted them for epilepsy in the pre-
vious year. This estimate is relatively close to the esti-
mated prevalence of epilepsy. Contrary to the neg-
ative impression of the primary health care system,
the data seem to suggest that people with epilepsy
seek help in the primary health care system. Never-
theless, a number of physicians, mostly paediatricians,
stated that they saw a higher percentage (>3%) of
the population for epilepsy; which may suggest that
either there is a higher prevalence of epilepsy in the
paediatric age group, or that epilepsy is over- d i a g-
nosed. Misdiagnosis is not uncommon in the paedi-
atric age group. This is particularly so in cases of fe-
brile seizures, which are often erroneously consid-
e red as epilepsy and often treated with long-term
AED therapy.
It has been estimated that 70% of people with
epilepsy can achieve seizure control with one AED5;
these are the people who might be expected to be
under the care of primary care physicians. Never-
theless, only 55% (n=289, range 0% to 100%) of pa-
tients were estimated by physicians to be on mono-
therapy and 60% (n=287, range 0% to 100%, medi-
an=70%) of patients were estimated to be seizure -
f ree. The survey showed that 59% (n=303, range 0%
to 100%) of patients are re f e rred to neurologists and
o n e - t h i rd for psychological support. Possible inter-
p retations could be either that the physicians are
dealing not only with low complexity cases, or that
t reatment is inadequate.  The former interpre t a t i o n
Table 2. Reasons given for being off treatment by people with active epilepsy16.
Reasons for not 
using medicine
Campinas and São José do Rio Preto
n % 95% CI 
Side effects 2 3.6 1.0 to 12.3
Do not know about treatment 7 12.7 6.3 to 24.0
Do not want treatment 28 50.9 38.1 to 63.6
Medical orientation 11 20 11.6 to 32.4
Never sought treatment 7 12.7 6.3 to 24.0
Total 55 100
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would reflect inefficient referral systems to second-
ary or tertiary health care level. The latter interpre-
tation would there f o re be more likely to be corre c t ,
as it is common to find inadequate AED therapy in
the community (either no AEDs or AEDs used in sub-
optimal dosage), and if the treatment were adequate
one would expect a lower re f e rral figure than that
o b s e rved. Either interpretation, together with the
fact that a majority (73%) of health professionals do
not feel confident in managing people with epilep-
s y, re i n f o rces the necessity of providing training in
the management of people with epilepsy. This would
be feasible, as 90% of physicians who did not feel
confident in managing people with epilepsy said they
would participate in a training course for impro v i n g
the quality of health management.
Social inclusion appeared to be an important issue,
as only half of the patients were thought to be social-
ly engaged. This number probably reflects the rate
of seizure - f reepatients, as patients who are not sei-
z u re - f ree have lower chances of getting a job or
going to school.
The situation assessment derived from phase 1 in
the catchment areas of the DP showed that the pre-
valence of epilepsy is similar to other re s o u rc e - p o o r
countries, and that the treatment gap is high. One of
the important factors contributing to the tre a t m e n t
gap is inadequacy of health care delivery. The situa-
tion could readily be changed in Brazil as the primary
health care system has the key elements re q u i red for
epilepsy management. To make this effective and eff i-
cient re q u i res: i) an established re f e rral network, ii)
continuous provision of AEDs, iii) close monitoring of
epilepsy management via the notification system
(Sistema de Informação da Atenção Básica - SIAB) a n d
iv) continuous education of health professionals. The
educational program should be broad spectrum and
include not only medical management, but also psy-
chological support for people with epilepsy and the
management of social aspects of epilepsy.
APPENDIX – DEMONSTRATION
PROJECT PROTOCOL DESIGN
This protocol is for a demonstration project test-
ing the feasibility of diagnosing and treating epilep-
sy at primary care level with rational use of first line
antiepileptic drugs (phenobarbital, phenytoin, car-
bamazepine and valproic acid). The long-term aim is
to integrate epilepsy management into the existing
p r i m a ry health delivery system in a sustainable man-
ner. If this project is shown to be effective it will be
recommended for implementation nationwide.
Overall aims
– To generate pro c e d u res that will improve the iden-
tification and management of people with epilep-
sy in urban areas within the existing primary health
c a re system and with community part i c i p a t i o n .
– To develop a model of epilepsy treatment at pri-
m a ry health level that can be applied nationwide
Specific aims
1 . To assess current management practices (iden-
tification, treatment, and follow-up) of patients with
epilepsy in urban areas of the country.
2. To estimate: a) the prevalence of active forms of
e p i l e p s y, b) the size of the treatment gap via an active
case-finding methodology, and c) changes that this
p roject may bring to these figures in the study are a .
3 . To ascertain the etiology and risk factors asso-
ciated with epilepsy in the community.
4 . To reduce and eradicate preventable causes of
epilepsy in the community.
5 . To ascertain the knowledge, attitudes and prac-
tice (KAP) of epilepsy amongst health practitioners
at primary health level prior to the study and after
they have undergone training for epilepsy.
6 . To develop technical norms for identification,
education, treatment and follow-up of patients with
epilepsy at primary health care level
7 . To carry out a feasibility study of the tre a t m e n t
of forms of epilepsy using first line antiepileptic dru g s
by primary health care physicians.
8 . To develop strategies for the implementation
of a cost-effective surgical program for the tre a t m e n t
of epilepsy.
9 . To develop a program for continuous pro f e s s i o n-
al education on epilepsy for primary health workers.
1 0 . To promote public awareness about epilepsy
via an educational program aimed at the community.
1 1 . To promote continuing education for primary
and secondary school teachers and dissemination of
information on epilepsy.
1 2 . To develop a program to de-stigmatize epilep-
sy and improve its social acceptance.
1 3 . To develop local advocacy and support gro u p s
for people with epilepsy.
1 4 . To reduce the economic and social burden of
epilepsy in the study areas.
Methodology
This demonstration project has three parts.
1. Epidemiological estimation – This will provide
a realistic estimation of the prevalence of epilepsy
and of untreated active epilepsy in the study area. 
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2. Service delivery (intervention study) – This will
cover the issues of diagnosis, AED treatment, follow-
up and referral networks.
3 . Education, social and community interv e n t i o n
– This will cover the educational and social aspects
of the project
Timeline
This is a four year project subdivided into six phas-
es as show in Figure 1.
Setting
The State of São Paulo is located in Southeast
Brazil. It is one of the country ’s most populous and
p ro s p e rous states. The region of Campinas, one of
the five large regions in the State of São Paulo, com-
prises 95 urban communities and has a population
of around 4.7 million. This region is responsible for
nine percent of the national GIP. The city of Campinas
has approximately one million inhabitants. The re g i o n
of São José do Rio Preto comprises 96 municipalities
and belongs to the eighth administrative region of
the State of São Paulo. The city of São José do Rio
Preto has approximately 340,000 inhabitants. 
The health care systems of Campinas and São José
do Rio Preto have primary, secondary, and tert i a ry care
centers. Primary care consists of home care, health
centers general support clinics, and diagnostic and
therapeutic support services (Serviço de Atendimen-
to Diagnóstico e Terapêutico - SADT). On a secondary
level, as well as SADT, there are specialized outpatient
clinics and local and macro regional hospitals. On a
t e rt i a ry level, there are specialized outpatient clinics
(University Hospitals), regional hospitals, and SADT.
The district of Barão Geraldo is located in the
n o rth of Campinas. It has a stru c t u red health care
system, with a primary health center that is under-
going expansion to serve 60% of the local popula-
tion of around 40,000 inhabitants. The health cen-
ter has four teams, each with a general physician, a
pediatrician and a nurse, responsible for the sub-
regions. A new program based on the concept of
“family physician” is being implemented and should
add to the existing setup in middle of 2002.
The hospital complex of the State University of
Campinas (UNICAMP) is the main re f e rral tert i a ry cen-
ter in the Campinas region. It has 597 beds and pro-
vides 450 thousand medical consultations a year, 22
thousand admissions, and 460 thousand non-med-
ical appointments (social services, psychology, occu-
pational therapy, audiology, pedagogy and physio-
therapy) each year. The Neurology Department of
UNICAMP has specialized clinics for adult and pedi-
atric patients with epilepsy, and includes a surg i c a l
p rogram for patients with medically re f r a c t o ryepilep-
sies. Patients with epilepsies are largely re f e rred by
health centers, emergency clinics and general clinics
in the city and region of Campinas (55%), from other
nearby regions (40%) and also from other states (5%).
The districts of Santo Antonio and Jaguaré are
located in the northwest, Region IX of São José do
Rio Preto. This has a stru c t u red primary health sys-
Fig 1. Timeline of demonstration project in Brazil.
Arq Neuropsiquiatr 2007;65(Supl 1) 11
tem with a family physician program and is open 24
hours. Each center is designed to provide 100%
health care cover for 55,000 inhabitants in the re g i o n
(25,000 are covered by the health center in Santo
Antonio and 30,000 in Jaguaré). In these two cen-
ters, there are 80 physicians and 16 nurses in total,
plus social assistants, technicians and auxiliary nurs-
es. There is no efficient re f e rral system to the tert i-
ary center for patients with epilepsy.
The hospital complex of Hospital de Base is a part
of the Faculty of Medicine and is the main re f e rr a l
t e rt i a rycenter in the São José do Rio Preto Region.
It has 550 beds and provides 30,000 out-patient con-
sultations and 3,320 admissions each month. The
N e u rology Department has specialized clinics for
adult and pediatric patients with epilepsy. A new pro-
longed video-EEG monitoring unit has been recent-
ly established and a surgical program for treatment
of epilepsy is being set up. 
Referral network for the study
Patients with a diagnosis of epilepsy screened by
the active search, self re p o rted or re f e rred by anoth-
er health center will initially be interviewed and exa-
mined by a physician at the primary health center,
who will complete the protocol and make a diagno-
sis. The patient will then be seen by a neurologist at
a tert i a rycenter who will confirm or refute the diag-
nosis and send the patient back to the re f e rring physi-
cian for treatment and/or follow-up. This process of
re f e rr a l - a n d - c o n t r a - re f e rral will take two to thre e
weeks. It is expected with time that physicians at the
p r i m a ry health center will become more knowledge-
able and confident in making the diagnosis, thus the
need for re f e rral for the purpose of diagnosis will
decrease.
Patients who do not respond to medication (not
attaining seizure - f reedom) within three months after
reaching the maximal tolerated dose of AED, or those
in whom unpredicted problems arise, will be re - e v a l-
uated by a neurologist at a tert i a ry center. The pro-
cess of re f e rral will take one to two weeks. In cases of
e m e rg e n c y, e.g. status epilepticus, patients will be
re f e rred to the emergency service of a tert i a ry center.
Definitions
For the purpose of this study the following defi-
nitions will be used:
Active epilepsy – Someone who has suff e redtwo
or more unprovoked seizures in the 12 months imme-
diately preceding identification by study officials is
defined as having active epilepsy.
U n p rovoked seizures – These are defined as
epileptic seizures not associated with a clear pre c i p-
itant or triggering factor (such as drug, fever, acute
head injury, acute cere b ro-vascular accident, acute
metabolic imbalance).
U n t reated epilepsy – Any patient with active
epilepsy who has not received regular antiepileptic
d rug treatment in the week preceding identification
by study officials is defined as having untreated epi-
lepsy.
Appropriate treatment – Appropriate treatment
of active epilepsy includes the diagnosis and tre a t-
ment of underlying causes, as well as treatment of
re c u rrent seizures according to international stan-
dards, using anti-epileptic drugs and surgery when-
ever indicated.
Treatment gap – This is defined as the diff e re n c e
between the number of people with active epilepsy
and the number whose seizures are being appro p r i-
ately treated in a given population at a given point
in time, expressed as a percentage.
Treatment of patients
Patients with a confirmed diagnosis of epilepsy
who wish to participate in this study will be enro l l e d
in the study protocol. Health assistants at the primary
health center will be responsible for explaining the
n a t u re of this study, obtaining written consent and
completing study entry forms (number 331/2002).
Physicians at the primary health centers will be re s-
ponsible for prescribing medication (following a gui-
deline for AED prescription), and completing the
medical report forms.
Demographic details, estimation of number of
s e i z u res, particularly convulsions, that the patient
has experienced in the previous, week, month, and
year will be recorded. A record of the current occu-
pational status of the patient (work and school) will
be made. If the patient is employed or attends school,
an estimation of absenteeism from work or school
due to epilepsy will be made and recorded.
The clinician or pediatrician will explain to the pa-
tient and relatives the importance of adherence to
the medication regime, and how the medication
should be used. They will also explain to the patients
about potential side-effects, and advise the patient
to re p o rt any experienced to the physician who start-
ed the treatment. Patients will receive a health card
with follow-up appointment dates. During the first
two months, each patient will re t u rn every two weeks
to adjust medication. Patients will also be evaluated
by a neurologist; after the initial assessment, each
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patient will re t u rn to primary care physicians every
t h ree months in the first year to check for compli-
ance, side-effects, and level of seizure - c o n t rol. In case
of doubt, severe or persistent side-effects or re c u r-
rent seizures, patients will be re-evaluated by neu-
rologists.
Each patient and/or parent will re c o rd seizure s ,
medication taken, any effects of treatment and oth-
er problems. Those patients working or at school will
be questioned about their attendance since the pre-
vious visit, and any changes of occupational status
will be recorded.
Patients may be withdrawal from the study if any
of the following situations arise:
– Patient or guardian decides against continuing
treatment.
– Patient is found to have a progressive neurolog-
ical disorder.
– Patient has re f r a c t o ry epilepsy (patient will be fol-
lowed-up at a tertiary center).
Treatment outcomes
At the end of the study, one objective and two
subjective assessments will be carried out to deter-
mine the effectiveness of treatment.
Objective assessment – This is defined by the num-
ber of seizures since the introduction of the AED.
– Excellent: Seizure-free.
– E ffective: > than 50% reduction in seizure fre-
quency.
– No effect: < than 50% reduction in seizure fre-
quency.
We arbitrarily chose 50% reduction in seizure fre-
quency as a cut-off for effectiveness; we will, how-
e v e r, re c o rdthe actual frequency of seizures for each
patient for later analysis.
P h y s i c i a n ’s assessment – The physicians will rate
w h e t h e r, in their opinion, treatment has impro v e d
each patient’s overall well-being significantly, a lit-
tle, or not at all.
P a t i e n t ’s or guardian's assessment – Patients or
g u a rdians will also be asked whether in their opin-
ion the overall well-being of the patient has im-
p roved significantly, a little or not at all since the ins-
titution of treatment. 
Outcome measures
A series of evaluations will be carried out to meas-
u re the effectiveness of this project. We will follow
the guidelines for measurements of results based on
the report from the Epilepsy Impact Meeting.
The outcomes to measure the pro j e c t ’s eff e c t i v e-
ness have been taken from the Global Campaign
Report on the Burden of Epilepsy.
1 . The overall effectiveness of the project in re-
ducing the treatment gap will be determined by the
two epidemiological estimations that will be carr i e d
out at the onset of the study and four years later,
measuring changes in the number of untreated pa-
tients between the two estimation points.
2 . The effectiveness of the management of peo-
ple with epilepsy at primary health care level will be
determined by:
2 . 1 . The clinical efficacy of the intervention (num-
ber of patients seizure - f ree and number with signif-
icant improvement in seizures).
2 . 2 . Safety and tolerability of treatment (num-
ber of people who drop-out due to side effects).
2 . 3 . Social changes observed in patients and com-
munity.
3 . The effectiveness of the training module to
induce changes in knowledge, attitudes and practice
among health professional will be measured by:
3 . 1 . Changes in the information re c o rded in KAP
q u e s t i o n n a i resprior to training and six months later.
3 . 2 . Changes in the number of patients identi-
fied and treated by the trainees.
4 . The effectiveness of the program to reduce the
social and economic burden will be measured by:
4 . 1 . The numbers of patients who re t u rn to school
or gainful work; or start to work or to go to school
for the first time. 
4 . 2 . Changes in the attendance re c o rd of those
at work and school.
Social and community intervention
Community education/school – The issue of stig-
ma in epilepsy and the lay perception and pre j u d i c e
against patients with epilepsy will be explored in dif-
ferent segments of society.
An educational program aimed at decreasing the
amount of social stigma in areas of social re l a t i o n s ,
employment, leisure activities, schooling etc, will be
developed. This will be aimed at local primary and
s e c o n d a ry school teachers because they exercise an
i m p o rtant role in their communities. The aim of this
p rogram will be to address attitudes re g a rding eti-
o l o g y, shame and the lack of infectiousness of epilep-
sy. A questionnaire on the public perception of epi-
lepsy will be completed by the teachers before and
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after the educational program as well by students to
assess changes.
The following activities will also be carried out in
the community:
– I n f o rmation dissemination about epilepsy thro u g h
the media.
– Distribution of material on epilepsy.
– Display of posters.
– Creation of a website.
Developing local advocacy/support group – We
will help create an advocacy/support group consist-
ing of local laymen and health professionals.
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